Source - Alliance News

Synairgen PLC - Southampton, England-based drug discovery and biotechnology company - Says the US National Institute of Allergy & Infectious Diseases has halted all patient recruitment in its phase 2/3 Covid-19 trial. The trial included the assessment of its inhaled SNG001 drug.

Explains that this decision is due to a significant shift in the nature of the pandemic. It would necessitate a substantial amendment of the study design that is not feasible in its multiple treatment-arm, platform trial.

Says a new trial design is needed to evaluate the efficacy of SNG001 against Covid-19 and that it is in discussions with lead investigators to try to identify an appropriate clinical trial to continue SNG001’s evaluation.

‘Conducting clinical trials in the time of Covid-19 is challenging but as important now as at the start of the pandemic. Even with an improved standard of care, there remains a critical need to prevent progression to severe disease and death. As such, we are actively seeking inclusion in platform trials for hospitalised patients and are working closely with the National Institutes of Health to also find a suitable trial for SNG001 in home-based patients,’ Chief Executive Richard Marsden says.

Current stock price: 20.96 pence, down 19%

Year-to-date change: down 88%

Copyright 2022 Alliance News Limited. All Rights Reserved.

Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. AJ Bell logo

Related Charts

Synairgen PLC (SNG)

+0.36p (+5.71%)
delayed 16:30PM